A physician is consulting with a newly diagnosed diabetes patient with early-stage Type 2 diabetes. The physician is considering a diabetes-specific treatment for the patient. The physician wants to see the patient lose bodyweight and observe a blood sugar drop by 2% or more (as measured by A1C). Based on this patient’s family history, it will be difficult to manage the patient. If the physician used Tirzepatide (presume it has been approved), what rationale would support that decision?
A. The drug is new on the market and improves the medical outcomes from older drugs like Ozempic and Trulicity.
B. The drug increases GIP and GLP-1 levels, thus providing a unique dual mechanism of action to target the underlying disease process.
C. The drug has an FDA indication for treating patients with unmanageable glucose levels in their bloodstream.
D. The drug safety profile is similar to that seen with other GLP-1 drugs on the market, and most patients have mild to moderate adverse events – if any.
Answer:B
A physician is consulting with a newly diagnosed diabetes patient with early-stage Type 2 diabetes. The physician is considering a diabetes-specific treatment for the patient. The physician wants to see the patient lose bodyweight and observe a blood sugar drop by 2% or more (as measured by A1C). Based on this patient’s family history, it will be difficult to manage the patient. If the physician used Tirzepatide (presume it has been approved), what rationale would support that decision?
A. The drug is new on the market and improves the medical outcomes from older drugs like Ozempic and Trulicity. B. The drug increases GIP and GLP-1 levels, thus providing a unique dual mechanism of action to target the underlying disease process. C. The drug has an FDA indication for treating patients with unmanageable glucose levels in their bloodstream. D. The drug safety profile is similar to that seen with other GLP-1 drugs on the market, and most patients have mild to moderate adverse events – if any.